Thalidomide Submitted for NDAs for Use In Leprosy and AIDS Cachexia
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Thalidomide Submitted for NDAs for Use In Leprosy and AIDS Cachexia

WARREN, N.J., Nov. 11, 1996 -- Celgene Corporation (Nasdaq: CELG) today reconfirmed that it will submit a New Drug Application (NDA) by the end of 1996 with the Food and Drug Administration for the use of thalidomide in the treatment of erythema nodosum leprosem (ENL), a disorder associated with leprosy.

The company met November 8 with the Dermatologic and Ophthalmic Drugs Advisory Committee to the FDA. Following the closed meeting, Celgene Chairman and CEO John W. Jackson said his company will move ahead with submission plans and is hoping for a timely and favorable review.

Celgene has completed the pivotal trial for the use of thalidomide in AIDS-related cachexia, a severe weight loss and wasting condition. Assuming satisfactory safety and efficacy data, the company plans to move forward to submit an NDA in this indication also.

Celgene Corporation, headquartered in Warren, N.J., uses proprietary expertise in small molecule chemistry to serve the pharmaceutical and allied industries.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities